CMPX has 36-month beta value of 0.73. Analysts have mixed views on the stock, with 5 analysts rating it as a “buy,” 5 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for CMPX is 85.86M, and currently, short sellers hold a 2.08% ratio of that float. The average trading volume of CMPX on November 15, 2024 was 456.31K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
CMPX) stock’s latest price update
The stock of Compass Therapeutics Inc (NASDAQ: CMPX) has decreased by -9.75 when compared to last closing price of 1.59. Despite this, the company has experienced a -20.28% fall in its stock price over the last five trading sessions. globenewswire.com reported 2024-11-13 that BOSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will participate in the following investor events during the month of November 2024.
CMPX’s Market Performance
Compass Therapeutics Inc (CMPX) has seen a -20.28% fall in stock performance for the week, with a -24.67% decline in the past month and a 20.59% surge in the past quarter. The volatility ratio for the week is 9.17%, and the volatility levels for the past 30 days are at 7.21% for CMPX. The simple moving average for the past 20 days is -17.30% for CMPX’s stock, with a -5.74% simple moving average for the past 200 days.
Analysts’ Opinion of CMPX
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see CMPX reach a price target of $5. The rating they have provided for CMPX stocks is “Buy” according to the report published on September 16th, 2024.
Jefferies gave a rating of “Buy” to CMPX, setting the target price at $8 in the report published on January 31st of the previous year.
CMPX Trading at -18.26% from the 50-Day Moving Average
After a stumble in the market that brought CMPX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -38.68% of loss for the given period.
Volatility was left at 7.21%, however, over the last 30 days, the volatility rate increased by 9.17%, as shares sank -22.85% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +0.35% upper at present.
During the last 5 trading sessions, CMPX fell by -20.28%, which changed the moving average for the period of 200-days by +14.80% in comparison to the 20-day moving average, which settled at $1.7352. In addition, Compass Therapeutics Inc saw -8.01% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for CMPX
Current profitability levels for the company are sitting at:
- -18.79 for the present operating margin
- 0.34 for the gross margin
The net margin for Compass Therapeutics Inc stands at -15.98. The total capital return value is set at -0.34. Equity return is now at value -32.01, with -29.93 for asset returns.
Based on Compass Therapeutics Inc (CMPX), the company’s capital structure generated 0.01 points at debt to capital in total, while cash flow to debt ratio is standing at -29.92. The debt to equity ratio resting at 0.01. The interest coverage ratio of the stock is -28.51.
Currently, EBITDA for the company is -48.47 million with net debt to EBITDA at 0.43. When we switch over and look at the enterprise to sales, we see a ratio of 61.6. The liquidity ratio also appears to be rather interesting for investors as it stands at 31.84.
Conclusion
To put it simply, Compass Therapeutics Inc (CMPX) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
